Meningococcal Vaccines
Conjugate, polysaccharide, and recombinant protein vaccines targeting serogroups A, B, C, W, and Y
This page catalogs 16 meningococcal vaccine products spanning US-licensed conjugate and recombinant vaccines, European formulations, discontinued polysaccharide products, and the WHO-prequalified MenAfriVac developed for the African meningitis belt. The catalog includes monovalent (MenC, MenA), quadrivalent (MenACWY), serogroup B (MenB), and the newest pentavalent (MenABCWY) vaccines.
Last updated: April 2026.
Meningococcal Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Menactra | MenACWY-DT conjugate vaccine | Sanofi Pasteur | Conjugate (diphtheria toxoid) | FDA Licensed, 2005 | First US MenACWY conjugate |
| Menveo | MenACWY-CRM conjugate vaccine | GSK (Novartis legacy) | Conjugate (CRM197) | FDA Licensed, 2010 | Currently US-licensed |
| MenQuadfi | MenACWY-TT conjugate vaccine | Sanofi Pasteur | Conjugate (tetanus toxoid) | FDA Licensed, 2020 | Newer MenACWY |
| Bexsero | MenB-4C vaccine | GSK (Novartis legacy) | Recombinant protein | FDA Licensed, 2015 | MenB vaccine |
| Trumenba | MenB-FHbp vaccine | Pfizer | Recombinant lipidated FHbp | FDA Licensed, 2014 | MenB vaccine |
| Penbraya | MenABCWY vaccine | Pfizer | Conjugate + recombinant | FDA Licensed, 2023 | First pentavalent meningococcal (ABCWY) |
| Penmenvy | MenABCWY vaccine | Sanofi | Conjugate + recombinant | FDA Licensed, 2025 | Second pentavalent meningococcal |
| Menomune | MenACWY polysaccharide vaccine | Sanofi Pasteur | Polysaccharide | FDA Licensed; Discontinued | Replaced by conjugate vaccines |
| Mencevax | MenACWY polysaccharide vaccine | GSK | Polysaccharide | Licensed (non-US); Discontinued | European polysaccharide; discontinued |
| Meningitec | MenC conjugate vaccine | Pfizer (Wyeth) | Conjugate | Licensed (non-US) | MenC only |
| Menjugate | MenC conjugate vaccine | GSK (Novartis) | Conjugate (CRM197) | Licensed (non-US) | MenC conjugate |
| NeisVac-C | MenC conjugate vaccine | Pfizer | Conjugate (tetanus toxoid) | Licensed (non-US) | MenC conjugate |
| Nimenrix | MenACWY-TT conjugate vaccine | Pfizer (GSK legacy) | Conjugate (tetanus toxoid) | EMA Authorized | European MenACWY |
| MenAfriVac | MenA conjugate vaccine | Serum Institute of India | Conjugate | WHO Prequalified | Developed for African meningitis belt |
| Menhibrix | MenCY-Hib conjugate vaccine | GSK | Conjugate combination | FDA Licensed, 2012; Discontinued | MenCY + Hib combination; discontinued |
| MCV4 (generic) | Various quadrivalent meningococcal | Various | Various | Various | Generic designation for MenACWY products |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026), EMA Medicines database, and WHO Prequalified Vaccines list. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.